With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-18-7,2-(Dicyclohexylphosphino)-2′,4′,6′-tri-i-propyl-1,1′-biphenyl,as a common compound, the synthetic route is as follows.
564483-18-7, Example 430 Production of N-{3-[(2-anilinoimidazo[1,2-b]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide A mixture of N-{3-[(2-aminoimidazo[1,2-b]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide (100 mg, 0.242 mmol), iodobenzene (32 mul, 0.290 mmol), tris(dibenzylideneacetone)dipalladium (0) (11 mg, 24.2 mumol), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (23 mg, 48.4 mumol), sodium tert-butoxide (34 mg, 0.362 mmol) and toluene (2 mL) was stirred under an argon atmosphere with heating at 80 C. for 5 hr. After the reaction mixture was allowed to cool to room temperature, saturated aqueous sodium hydrogencarbonate solution was added to the mixture, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and filtrated. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate/hexane=0/100?50/50) to give the title compound (19 mg, 16%) as a pale-green powder. 1H-NMR (DMSO-d6, 300 MHz) delta 6.78 (1H, t, J=7.3 Hz), 6.96-7.07 (2H, m), 7.18-7.25 (2H, m), 7.36-7.50 (3H, m), 7.65-7.72 (3H, m), 7.79 (1H, t, J=7.6 Hz), 7.98 (2H, d, J=9.2 Hz), 8.18-8.32 (2H, m), 8.91 (1H, s), 10.58 (1H, s).
564483-18-7 2-(Dicyclohexylphosphino)-2′,4′,6′-tri-i-propyl-1,1′-biphenyl 11155794, achiral-phosphine-ligands compound, is more and more widely used in various fields.
Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; US2009/137595; (2009); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate